Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the maximum tolerated dose (MTD) of azacitidine and
gemcitabine in subjects with previously untreated and unresectable pancreatic cancer. Also to
determine the effect of azacitidine therapy on DNA methylation in peripheral blood cells.